Prana Biotechnology (PRAN)

[Basque Trader]

AD/PD 2011 Conference in Barcelona (Spain)
March 9 - 13.

At least two presentations regarding PRANA's activities

PBT434: A Novel 8-hydroxyquinazolin-4 (3H)-one Provides Robust Neuroprotection in Transgenic and Toxin Animal Models of PD Associated with Reduced Nigral Alpha-synuclein and Elevated PARK7 (DJ-1)

R. Cherny1,2, J. George2, N. Critch2, M. Cortes2, X. Liu2, M. Nurjono2, K. Laughton2, I. Volitakis2, C. Masters2, J. Parsons1, E. Gautier1, K. Barnham3, A. Bush2, D. Finkelstein2
1Prana Biotechnology Ltd, 2The Mental Health Research Institute, The University of Melbourne, 3Bio21 Research Institute, The University of Melbourne, Parkville, VIC, Australia

http://www.abstractserver.com/ADPD2011/planner/index.php?go=abstract&action=abstract_iplanner&absno=1398&ADPD2011_NEW=girq8o7or3naj6oqcgmvd1n8e7&ADPD2011_NEW=girq8o7or3naj6oqcgmvd1n8e7

Aß and a-synuclein Oligomers as Tractable Targets for Alzheimer's and Parkinson's Disease Diagnostics and Therapeutics

C. Masters
Mental Health Research Institute; The University of Melbourne, Carlton, VIC, Australia

http://www.abstractserver.com/ADPD2011/planner/index.php?go=abstract&action=abstract_iplanner&absno=78&ADPD2011_NEW=leii6kc03u5t9255l28pj0hki7&ADPD2011_NEW=leii6kc03u5t9255l28pj0hki7